Metastatic

Localized

HER 2-

IRB# 18340
New study to be available soon

HER 2+

IRB# 18147
New study to be available soon

1st Line

2nd Line

No Trials Currently Available

1st Line

2nd Line

IRB #16058
A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer (CheckMate 577: CHECKpoint pathway and nivolumab clinical Trial Evaluation 577)

IRB #12071
New study to be available soon

IRB# 16893
New study to be available soon

Adjuvant

http://www.ohsu.edu/research/rda/so/knight.php